Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 19/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 19/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30224406 | 0.78 | GRIN1 (0.36) | GRIN1GRIN2B | |
| SCHEMBL17969325 | 0.78 | HSD17B10 (0.39) | GRIN1GRIN2B | |
| SCHEMBL23994190 | 0.74 | KMO (0.55) | CYP17A1CYP1A2 | |
| SCHEMBL22775781 | 0.73 | KMO (0.46) | GRIN1GRIN2B | |
| SCHEMBL30224777 | 0.73 | CYP17A1 (0.36) | CYP17A1CYP1A2 | |
| SCHEMBL23993406 | 0.73 | CYP17A1 (0.36) | CYP17A1CYP1A2 | |
| SCHEMBL23994569 | 0.73 | KCNJ6 (0.34) | GRIN1GRIN2B | |
| SCHEMBL25282474 | 0.72 | GRIN1 (0.41) | GRIN1GRIN2BCYP17A1CYP1A2 | |
| SCHEMBL22771412 | 0.72 | GRIN1 (0.37) | GRIN1GRIN2B | |
| SCHEMBL3605436 | 0.72 | RAB9A (0.48) | GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240043427-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| CN-115698009-A | CD73 inhibiting 2,4-dioxopyrimidine compounds | 吉利德科学公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | GRIN1 3028/4885GRIN2B 3139/4885CYP17A1 4392/4885 |
| US-20240043427-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | GRIN1 3028/4885GRIN2B 3139/4885CYP17A1 4392/4885 |
| US-12110294-B2 | CD73 compounds | ENTPD5, ENTPD1, NT5E | GRIN1 2872/4885GRIN2B 2995/4885CYP17A1 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.